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ABSTRACT
Introduction: There is inconclusive evidence to support any specific criteria for starting pharma-
cologic therapy after diet in women with gestational diabetes mellitus (GDM). We aimed to ana-
lyze the most used criteria for starting pharmacologic treatment for patients with GDM.
Material and methods: Electronic databases were searched from their inception to September
2017. We included all the randomized controlled trials (RCTs) of GDM managed initially by diet
and exercise reporting criteria for starting pharmacologic therapy. RCTs in women with pregesta-
tional diabetes were excluded. Data regarding glucose values used for starting pharmacologic
therapy were extracted and carefully reviewed.
Results: We included 15 RCTs (4307 women) in the meta-analysis. For fasting glucose target,
8/14 (57%) used a value lower or equal to 90mg/dL and the remainder used values <99mg/dL.
Of the 10 RCTs targeting 2-h postprandial values, the majority (9/10, 90%) used 120mg/dL. The
majority of RCTs (13/15, 87%) recommended pharmacologic therapy if either 1 or 2 values per
1- or 2-week period were higher than the target values: 7/13 (54%) used 1 value and 6/13 (46%)
used 2 values higher than target values. One RCT (7%) used >50% of the values higher than the
target values and another one (7%) used >30%.
Conclusion: The majority of RCTs (87%) used very tight criteria of either 1 or 2 values over the
target values in the 1 or 2-week period for starting pharmacologic treatment for patients with
GDM; more than 50% used 2 values.
KEY MESSAGE
 Pharmacologic therapy should be considered in women with gestational diabetes when, des-
pite an adequate diet and exercise, 1 or 2 blood glucose values are over the target values of
90mg/dL fasting or 120mg/dL 2-hour postprandial over 1 or 2 weeks.
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Introduction
Gestational diabetes mellitus (GDM) is a common dis-
order complicating pregnancy, with short- and long-
term consequences for the mother, fetus and new-
born. It has been estimated that about 6–18% or more
of all the pregnancies are complicated by GDM in
pregnancy, depending on the country, on the charac-
teristics of the study population and on the GDM
screening method used [1–65]. The latest reports from
the International Diabetes Federation (IDF) estimate
that worldwide, approximately one in seven births in
2015 were complicated by some form of hypergly-
cemia during pregnancy [53].
The aim of the treatment of GDM is to prevent
maternal and neonatal morbidity and mortality by
achieving glucose levels similar to those in nondiabetic
women, while avoiding hypoglycemia.
Management for women with GDM includes diet
[64], physical activity [60], and oral hypoglycemic
agents and/or insulin [66] as needed. Nutrition coun-
seling and physical activity should be the primary ini-
tial interventions in the management of GDM. Women
with GDM must receive practical nutritional education
and counseling that will empower them to choose the
right quantity and quality of food and level of physical
activity. If lifestyle modification with diet and exercise
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fails to achieve glucose control, metformin, glyburide,
or insulin should be considered as safe and effective
treatment options for GDM [54]. However, the criteria
for starting pharmacologic therapy after initial diet
and exercise therapy for GDM remain controversial.
Objective
The aim of this review was to conduct a systematic
review of randomized controlled trials (RCTs) to analyze
the criteria for starting pharmacologic therapy for GDM
after initial diet and exercise treatment was introduced.
Materials and methods
Search strategy
This review was performed according to the PRISMA
statement recommended for systematic review
[55–57]. The review protocol was designed a priori to
define methods for collecting, extracting and analyzing
the data. The research was conducted with the use of
Medline, Ovid, and Cochrane Library as electronic
databases. The trials were identified with the use of a
combination of the following text words: “gestational
diabetes”, “GDM”, “diabetes in pregnancy”, “therapy”,
“treatment”, “diet”, “exercise”, “trial” and “randomized”
from the inception of each database through
September 2017. Review of articles also included the
abstracts of all references that were retrieved from the
search. No restrictions for language or geographic
location were applied.
Study selection
We included all RCTs studying women with GDM that
started with nonpharmacologic treatment such as diet
and exercise, and proceeded to pharmacologic therapy
only after initial nonpharmacologic treatments had
failed. RCTs in women with pregestational diabetes
(DM) were excluded. Studies in women with impaired
glucose tolerance, and studies not reporting criteria
for starting pharmacologic therapy for GDM were
also excluded.
Data extraction and risk of bias assessment
The risk of bias in each included study was assessed
using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions. Seven domains
related to risk of bias were assessed in each included
trial since there is evidence that these issues are asso-
ciated with biased estimates of treatment effect: (1)
random sequence generation; (2) allocation
concealment; (3) blinding of participants and person-
nel; (4) blinding of outcome assessment; (5) incom-
plete outcome data; (6) selective reporting; and (7)
other bias. Review authors’ judgments were catego-
rized as “low risk”, “high risk” or “unclear risk” of
bias [55].
Data extraction
For each trial, data regarding our primary objective,
criteria for starting pharmacologic therapy for GDM,
were extracted and carefully reviewed. We also
reviewed the type of glucose screening, frequency of
glucose monitoring, and target glucose values, as they
are closely associated with our primary objective. The
types of GDM screening were defined as one-step, i.e.
75 g 2-h glucose load, and two-step, i.e. 50 g 1-h glu-
cose load, followed if abnormal by a 100 g 3-h glucose
load test.
Results
We identified 51 RCTs on therapy for diabetes in preg-
nancy, and these were assessed for eligibility (Figure 1)
[1–51]; 36 were excluded; we included 15 trials of 4307
women in our review [1–15]. Figure 2 shows the risk of
bias of each of these trials. Most of them had high risk
of performance bias and detection bias, and low risk of
attrition bias and reporting bias.
Table 1 shows the characteristics of the included tri-
als. No RCT compared differing criteria for starting
pharmacologic therapy after the diagnosis of GDM
and initial diet therapy. Eight out of the 15 included
RCTs (53%) used the one-step diagnostic test
[1,4–6,8–10,12]; six (40%) trials used the two-step test
[2,3,7,11,13,15]; and Spaulonci et al. used either the
one- or two-step test [14]. Sample size ranged from 23
[6] to 1000 women [5]. For each RCT we reported
inclusion and exclusion criteria of the enrolled patients
when described in the RCT.
Table 2 shows the methods of management of
women included in trials. In most of them (10 RCTs,
67%) glucose monitoring was assessed four times daily
(fasting and either 1, 1.5 or 2 h after each of the three
main meals – breakfast, lunch, and dinner)
[1,5,7–9,11–15]; 2 (13%) trials used seven times daily
approach (i.e. fasting, preprandial before lunch and
dinner, 2 h after each main meal) [2,10]; 1 (7%) trial
checked nine times daily monitoring, (fasting and 1
and 2 h after each main meal); (3) 1 (7%) trial moni-
tored six times daily (fasting, preprandial before lunch
and dinner, 1 h after each main meal); (4) and 1 (8%)
trial did not describe the monitoring approach [6].
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Fourteen out of 15 (93%) RCTs used fasting glucose
as a target [1–5,7–15], the higher fasting value allowed
was 99mg/dL: 8/14 (57%) used a value lower or equal
to 90mg/dL as target [1–4,9,10,12,15], 5 (36%) used
95mg/dL [7,8,11,13,14], and 1 (7%) used 99mg/dL [5].
Of the 10 RCTs using the 2-h postprandial value as tar-
get, 9 (90%) had 120mg/dL as cutoff [2,6,9–15], and 1
used 126mg/dL as the cutoff [5]. Of the four RCTs using
1-h postprandial value as target, three (75%) had
120mg/dL as cutoff [3,4,7], and one 140mg/dL [1].
One RCT used the 1.5-h postprandial value of 120mg/
dL as a target8. One RCT used the 2-hour postprandial
target of 120mg/dL only [6]. One RCT considered also
the Hb1Ac value of 6.0 g/dL [9].
Regarding the type of initial nonpharmacologic
treatment, 15 RCTs (100%) reported a new diet was
recommended, while 4 RCTs (27%) reported that exer-
cise was also recommended.
Regarding the glucose values used for starting
pharmacologic therapy after diet and exercise, there
were seven different criteria that the included stud-
ies applied:
 Thirteen trials (87%) used 1 or 2 values higher than
the target values [1,2,4–13,15]; of these, 7/13 (54%)
used 1 value higher than target values
[2,6,7,9,10,13,15], and 6/13 (46%) used 2 values
higher than target values [1,4,5,8,11,12]. Of these
13 trials, 5 (38%) assessed 1 week of glucose values
[2,11–13,15], 7 (54%) assessed 2 weeks [1,4–7,9,10],
1 assessed either 2 or 4 weeks [8], and in 1 trial the
finding of 1 fasting value higher than the target
value was enough to start pharmacologic ther-
apy [7].
 One trial (7%) used >50% of the values higher
than the target values in 1 week [3].
 One trial (7%) used >30% of the values higher
than the target values in 1 week [14].
Discussion
Main findings
This systematic review of 15 RCTs, including 4307
women, evaluated the criteria for starting pharmaco-
logic therapy in women with GDM. We did not find
any RCT comparing different criteria for starting
pharmacologic therapy. All 15 RCTs included women
with GDM. The most common features for these RCTs
were that they used the one-step test (with 75-g glu-
cose load) for GDM diagnosis (8/15; 53%); 67% (10/15
RCTs) monitored glucose values four times per day;
and 50% (7/14) used a fasting target of 90mg/dL and
90% (9/10) a 2-h target of 120mg/dL.
Regarding our main aim, we found seven different
criteria for starting pharmacologic therapy after diet in
women with GDM. The most commonly used criterion
was either 1 or 2 values per 1 or 2-week period higher
than the target values (7 RCTs, 47%), of which four
used only 1 value (27% of total), and three (20% of
total) used two values.
There were several limitations in our study. No trials
comparing a policy of very tight versus tight glycemic
control and assessing the criteria for starting pharma-
cologic therapy in diabetes in pregnancy could be
identified. Therefore, a standard meta-analysis was not
feasible. The clinical heterogeneity within the trials
was very high. The included trials used different proto-
col management, diagnostic test, initial medication
therapy, glucose monitoring, and target glucose val-
ues. Moreover, not all RCTs considered the same
Figure 1. Flow diagram of studies identified in the systematic
review. (Prisma template [Preferred Reporting Item for
Systematic Reviews and Meta-analyses]).
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outcomes. The impossibility to compare the studies
was the major shortcoming of our review.
Interpretation and conclusions
When evaluating RCTs that included criteria for start-
ing pharmacologic therapy in women with GDM, the
most common criteria for GDM diagnosis was the one-
step test. The most common frequency for glucose
monitoring was four times per day, i.e. fasting and
after each main meal, using a fasting of 90mg/dL and
a 2 h of 120mg/dL as targets. Importantly, we found
seven different criteria for starting pharmacologic ther-
apy after diet. Most studies used very tight criteria of
either 1 or 2 values in one- or 2-week period higher
than the target values, of which 7 studies used only 1
value (47% of total), and 6 used 2 values (40% of
total). While very tight (1 or 2 abnormal target values
in 1 or 2 weeks) versus tight (> 30% or >50%
abnormal target values in 1 week) criteria for starting
pharmacologic therapy did not seem to affect out-
comes, it is impossible to really assess this comparison
given the absence of head-to-head RCTs with this
study design. Furthermore, the outcomes are in part
the effect of the pharmacologic therapy used after the
initial nonpharmacologic treatment.
Our study underlines the unmet need to standard-
ize worldwide GDM screening and management.
Regarding screening, recent RCTs and a meta-analysis
demonstrate that one-step approach seems to be the
best screening method [65]. Additionally, regarding
GDM management, international societies do not
agree on the criteria to switch from diet to pharmaco-
logical therapy and which is the first medication to
adopt (e.g. insulin versus oral hypoglycemic agents).
Therefore, future well-designed and properly pow-
ered RCTs are needed to answer many questions
regarding GDM diagnosis and management, including
Figure 2. Assessment of risk of bias. (A) Summary of risk of bias for each trial; Plus sign: low risk of bias; minus sign: high risk of
bias; question mark: unclear risk of bias. (B) Risk of bias graph about each risk of bias item presented as percentages across all
included studies.
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which criteria should be used to recommend pharma-
cologic therapy because of failed diet therapy.
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